Prognostic indicators for papillary thyroid carcinoma

References

• Sherman SI. Thyroid carcinoma. Lancet. 2003;361:501–511.
   PubMed Web of Science ®Google Scholar
• Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140:317–322.
   PubMed Web of Science ®Google Scholar
• Leenhardt L, Bernier MO, Boin-Pineau MH, et al. Advances in diagnostic practices affect thyroid cancer incidence in France. Eur J Endocrinol. 2004;150:133–139.
   PubMed Web of Science ®Google Scholar
• Ito Y, Kudo T, Kobayashi K, et al. Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5,768 patients with average 10-year followup. World J Surg. 2012;36:1274–1278.
   PubMed Web of Science ®Google Scholar
• Ito Y, Ichihara K, Masuoka H, et al. Establishment of an intraoperative staging system (iStage) by improving UICC TNM classification system for papillary thyroid carcinoma. World J Surg. 2010;34:2570–2580.
   PubMed Web of Science ®Google Scholar
• Mazurat A, Torroni A, Hendricson-Rebozamt K, et al. The age factor in survival of a population cohort of well-differentiated thyroid cancer. Endocr Connect. 2013;2:154–160.
   PubMed Web of Science ®Google Scholar
• Sugitani I, Kasai N, Fujimoto Y, et al. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the followup period. Surgery. 2004;135:139–148.
   PubMed Web of Science ®Google Scholar
• Matsuzu K, Sugino K, Masudo K, et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg. 2014;38(1):68–79.
   PubMed Web of Science ®Google Scholar
• Siironen P, Louhimo J, Nordling S, et al. Prognostic factors in papillary thyroid cancer: an evaluation of 601 consecutive patients. Tumour Biol. 2005;26(2):57–64.
   PubMed Web of Science ®Google Scholar
• Cady B, Rossi R. An expanded view of risk group definition in differentiated thyroid carcinoma. Surgery. 1988;104:947–953.
   PubMed Web of Science ®Google Scholar
• Miyauchi A, Kudo T, Kihara M, et al. Relationship of biochemically persistent disease and thyroglobulin-doubling time to age at surgery in patients with papillary thyroid carcinoma. Endocr J. 2013;60:415–421.
   PubMed Web of Science ®Google Scholar
• Ito Y, Miyauchi A, Kihara M, et al. Prognostic significance of young age in papillary thyroid carcinoma: analysis of 5,733 patients with 150 months’ follow-up. Endocr J. 2014;61:491–497.
   PubMed Web of Science ®Google Scholar
• Cho JS, Yoon JH, Park MH, et al. Age and prognosis of papillary thyroid carcinoma: retrospective stratification into three groups. J Korean Surg Soc. 2012;83:259–266.
   PubMedGoogle Scholar
• Akslen LA, Myking AO, Salvesen H, et al. Prognostic importance of various clinicopathological features in papillary thyroid carcinoma. Eur J Cancer. 1992;29A(1:44–51.
   Web of Science ®Google Scholar
• Yorke E, Melck A, Wiseman SM. Impact of sex on the clinicopathological characteristics and prognosis of papillary thyroid cancer. Can J Surg. 2016;59(4):287–288.
   PubMed Web of Science ®Google Scholar
• Ito Y, Kakudo K, Hirokawa M, et al. Biological behavior and prognosis of familial papillary thyroid carcinoma. Surgery. 2009;145:100–105.
   PubMed Web of Science ®Google Scholar
• Toriato A, Boschin I, Casara D, et al. Papillary thyroid carcinoma: factors influencing recurrence and survival. Ann Surg Oncol. 2008;15:1518–1522.
   PubMed Web of Science ®Google Scholar
• Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.
   Google Scholar
• Mazzaferri EL. Management of low-risk differentiated thyroid cancer. Endocr Pract. 2007;13:498–512.
   PubMedGoogle Scholar
• Roti E, Degli Uberti EC, Bondanelli M, et al. Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. Eur J Endocrinol. 2008;159:659–673.
   PubMed Web of Science ®Google Scholar
• Ito Y, Kudo T, Kihara M, et al. Prognosis of low-risk papillary thyroid carcinoma patients: its relationship with the size of primary tumors. Endocr J. 2012;59:119–125.
   PubMed Web of Science ®Google Scholar
• Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988 Dec;104(6):947–953.
   PubMed Web of Science ®Google Scholar
• Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer. 2005;103:2269–2273.
   PubMed Web of Science ®Google Scholar
• Fukushima M, Ito Y, Hirokawa M, et al. Prognostic impact of extrathyroid extension and clinical lymph node metastases in papillary thyroid carcinoma depend on carcinoma size. World J Surg. 2010;34:3007–3014.
   PubMed Web of Science ®Google Scholar
• Sugitani I, Toda K, Yamada K, et al. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg. 2010;34:1222–1231.
   PubMed Web of Science ®Google Scholar
• Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg. 2010;34(1):28–35.
   PubMed Web of Science ®Google Scholar
• Sobin LH, Wittekind CH eds. UICC: TNM classification of malignant tumors. 7th. New York: Willy-Liss; 2009.
   Google Scholar
• Popadich A, Levin O, Lee JC, et al. A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. Surgery. 2011;150(6):1048–1057.
   PubMed Web of Science ®Google Scholar
• Sancho JJ, Lennard TW, Paunovic I, et al. Prophylactic central neck disection in papillary thyroid cancer: a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg. 2014;399(2):155–163.
   PubMed Web of Science ®Google Scholar
• Sywak M, Cornford L, Roach P, et al. Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery. 2006;140(6):1000-5;discussion 1005-7.
   PubMed Web of Science ®Google Scholar
• Lee J, Song Y, Soh EY. Prognostic significance of the number of metastatic lymph nodes to stratify the risk of recurrence. World J Surg. 2014 Apr;38(4):858–862.
   PubMed Web of Science ®Google Scholar
• Adam MA, Pura J, Goffredo P, et al. Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer. J Clin Oncol. 2015 Jul 20;33(21):2370–2375.
   PubMed Web of Science ®Google Scholar
• Park YM, Wang SG, Lee JC, et al. Metastatic lymph node status in the central compartment of papillary thyroid carcinoma: a prognostic factor of locoregional recurrence. Head Neck. 2016 Apr;38(Suppl 1):E1172–6.
   PubMedGoogle Scholar
• Wang LY, Palmer FL, Nixon IJ, et al. Central lymph node characteristics predictive of outcome in patients with differentiated thyroid cancer. Thyroid. 2014 Dec;24(12):1790–1795.
   PubMed Web of Science ®Google Scholar
• Ito Y, Fukushima M, Tomoda C, et al. Prognosis of patients with papillary thyroid carcinoma having clinically apparent metastases to the lateral compartment. Endocr J. 2009;56(6):759–766.
   PubMed Web of Science ®Google Scholar
• Randolph GW, Duh QY, Heller KS, et al. American Thyroid Association surgical affairs committee’s taskforce on thyroid cancer nodal surgery. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 2012 Nov;22(11):1144–1152.
   PubMed Web of Science ®Google Scholar
• Sugitani I, Kasai N, Fujimoto Y, et al. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery. 2004 Feb;135(2):139–148.
   PubMed Web of Science ®Google Scholar
• DeGroot LJ, Kaplan EL, McCormik M, et al. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71(2):414–424.
   PubMed Web of Science ®Google Scholar
• Mazzaferri EL, Jhiang SM. Long term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418–428.
   PubMed Web of Science ®Google Scholar
• Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338(5):297–306.
   PubMed Web of Science ®Google Scholar
• Leger AF. Distant metastasis of differentiated thyroid cancers. Diagnosis by 131 iodine (I 131) and treatment. Ann Endocrinol (Paris). 1995;56(3):205–208.
   PubMed Web of Science ®Google Scholar
• Hoie J, Stenwig AE, Kullmann G, et al. Distant metastases in papillary thyroid cancer. A review of 91 patients. Cancer. 1988;61(1):1–6.
   PubMed Web of Science ®Google Scholar
• Shaha AR, Shah JP, Loree TR. Differentiated thyroid cancer presenting initially with distant metastasis. Am J Surg. 1997;174(5):474–476.
   PubMed Web of Science ®Google Scholar
• Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892–2899.
   PubMed Web of Science ®Google Scholar
• McCormack KR. Bone metastases from thyroid carcinoma. Cancer. 1966;19(2):181–184.
   PubMed Web of Science ®Google Scholar
• Marcocci C, Pacini F, Elisei R, et al. Clinical and biologic behavior of bone metastases from differentiated thyroid carcinoma. Surgery. 1989;106(6):960–966.
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Challeton C, de Vathaire F, et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med. 1996;37(4):598–605.
   PubMed Web of Science ®Google Scholar
• Proye CA, Dromer DH, Camail Le BM, et al. Is it still worthwhile to treat bone metastases from differentiated thyroid carcinoma with radioactive iodine? World J Surg. 1992;164:640–645.
   PubMed Web of Science ®Google Scholar
• Pittas AG, Adler M, Fazzari M, et al. Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid. 2000;10(3):261–268.
   PubMed Web of Science ®Google Scholar
• Fanchiang JK, Lin JD, Huang MJ, et al. Papillary and follicular thyroid carcinomas with bone metastases: a series of 39 cases during a period of 18 years. Chang Keng 1 Hsueh Tsa Chih. 1998;21(4):377–382.
   PubMedGoogle Scholar
• Lin JD, Huang MJ, Juang JH, et al. Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases. Thyroid. 1999;9(12):1227–1235.
   PubMed Web of Science ®Google Scholar
• Bernier MO, Leenhardt L, Hoang C, et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2001;86(4):1568–1573.
   PubMed Web of Science ®Google Scholar
• Ruegemer JJ, Hay ID, Bergstralh E, et al. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab. 1988;67(3):501–508.
   PubMed Web of Science ®Google Scholar
• Casara D, Rubello D, Saladini G, et al. Distant metastases in differentiated thyroid cancer: long-term results of radioiodine treatment and statistical analysis of prognostic factors in 214 patients. Tumori. 1991;77(5):432–436.
   PubMed Web of Science ®Google Scholar
• Dinneen SF, Valimaki MJ, Bergstralh EJ, et al. Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab. 1995;80(7):2041–2045.
   PubMed Web of Science ®Google Scholar
• Charbord P, L’Heritier C, Cukersztein W, et al. Radioiodine treatment in differentiated thyroid carcinomas. Treatment of first local recurrences and of bone and lung metastases. Ann Radiol (Paris). 1977;20(8):783–786.
   PubMedGoogle Scholar
• Niederle B, Roka R, Schemper M, et al. Surgical treatment of distant metastases in differentiated thyroid cancer: indication and results. Surgery. 1986;100(6):1088–1097.
   PubMed Web of Science ®Google Scholar
• Pacini F, Cetani F, Miccoli P, et al. Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World J Surg. 1994;18(4):600–604.
   PubMed Web of Science ®Google Scholar
• Pochin EE. Radioiodine therapy of thyroid cancer. Semin Nucl Med. 1971;1(4):503–515.
   PubMedGoogle Scholar
• Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med. 1981;70(3):511–518.
   PubMed Web of Science ®Google Scholar
• Tubiana M, Haddad E, Schlumberger MJ, et al. External radiotherapy in thyroid cancers. Cancer. 1985;55(9:Suppl):2062-2071.
   Web of Science ®Google Scholar
• Sanders LE, Cady B. Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. Arch Surg. 1998;133(4):419–425.
   PubMedGoogle Scholar
• Chiras J, Sola-Martinez MT, Weill A, et al. Percutaneous vertebroplasty. Rev Med Intern. 1995;16(11):854–859.
   PubMed Web of Science ®Google Scholar
• Cotten A, Dewatre F, Cortet B, et al. Percutaneous vertebroplasty for osteolytic metastases and myeloma: effects of the percentage of lesion filling and the leakage of methyl methacrylate at clinical follow-up. Radiology. 1996;200(2):525–530.
   PubMed Web of Science ®Google Scholar
• Smit JW, Vielvoye GJ, Goslings BM. Embolization for vertebral metastases of follicular thyroid carcinoma. J Clin Endocrinol Metab. 2000;85(3):989–994.
   PubMed Web of Science ®Google Scholar
• Showalter TN, Siegel BA, Moley JF, et al. Prognostic factors in patients with well-differentiated thyroid cancer presenting with pulmonary metastasis. Cancer Biother Radiopharm. 2008;23(5):655–659.
   PubMed Web of Science ®Google Scholar
• Cho SW, Choi HS, Yeom GJ, et al. Long-term prognosis of differentiated thyroid cancer with lung metastasis in Korea and its prognostic factors. Thyroid. 2014;24(2):277–286.
   PubMed Web of Science ®Google Scholar
• Ronga G, Filesi M, Montesano T, et al. Lung metastases from differentiated thyroid carcinoma. A 40 years’ experience. Q J Nucl Med Mol Imaging. 2004;48(1):12–19.
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Arcangioli O, Piekarski JD, et al. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med. 1988;29(11):1790–1794.
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Tubiana M, de Vathaire F, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1986;63(4):960–967.
   PubMed Web of Science ®Google Scholar
• Blankenship DR, Chin E, Terris DJ. Contemporary management of thyroid cancer. Am J Otolaryngol. 2005;26(4):249–260.
   PubMed Web of Science ®Google Scholar
• Bernard DM, Sperduto PW, Souhami L, et al. Stereotactic radiosurgery in the management of brain metastases from primary thyroid cancers. J Neurooncol. 2010;98(2):249–252.
   PubMed Web of Science ®Google Scholar
• Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab. 1997;82(11):3637–3642.
   PubMed Web of Science ®Google Scholar
• Kim IY, Kondziolka D, Niranjan A, et al. Gamma knife radiosurgery for metastatic brain tumors from thyroid cancer. J Neurooncol. 2009;93(3):355–359.
   PubMed Web of Science ®Google Scholar
• McWilliams RR, Giannini C, Hay ID, et al. Management of brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 years. Cancer. 2003;98(2):356–362.
   PubMed Web of Science ®Google Scholar
• Pazaitou Panayiotou K, Kaprara A, Chrisoulidou A, et al. Cerebellar metastasis as first metastasis from papillary thyroid carcinoma. Endocr J. 2005;52(6):653–657.
   PubMed Web of Science ®Google Scholar
• Salvati M, Frati A, Rocchi G, et al. Single brain metastasis from thyroid cancer: report of twelve cases and review of the literature. J Neurooncol. 2001;51(1):33–40.
   PubMed Web of Science ®Google Scholar
• Al Dhahri SF, Al Amro AS, Al Shakwer W, et al. Cerebellar mass as a primary presentation of papillary thyroid carcinoma: case report and literature review. Head Neck Oncol. 2009;1:23.
   PubMedGoogle Scholar
• Aguiar PH, Agner C, Tavares FR, et al. Unusual brain metastases from papillary thyroid carcinoma: case report. Neurosurgery. 2001;49(4):1008–1013.
   PubMed Web of Science ®Google Scholar
• Hjiyiannakis P, Jefferies S, Harmer CL. Brain metastases in patients with differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol). 1996;8(5):327–330.
   PubMedGoogle Scholar
• Andersen PE, Kinsella J, Loree TR, et al. Differentiated carcinoma of the thyroid with extrathyroidal extension. Am J Surg. 1995 Nov;170(5):467–470.
   PubMed Web of Science ®Google Scholar
• Ortiz S, Rodríguez JM, Soria T, et al. Extrathyroid spread in papillary carcinoma of the thyroid: clinicopathological and prognostic study. Otolaryngol Head Neck Surg. 2001 Mar;124(3):261–265.
   PubMed Web of Science ®Google Scholar
• Santos MJ, Bugalho MJ. Papillary thyroid carcinoma: different clinical behavior among pT3 tumors. Endocrine. 2016 Sep;53(3):754–760.
   PubMed Web of Science ®Google Scholar
• Lee HS, Park C, Kim SW, et al. Correlation of minimal extrathyroidal extension with pathologic features of lymph node metastases in patients with papillary thyroid carcinoma. J Surg Oncol. 2015 Nov;112(6):592–596.
   PubMed Web of Science ®Google Scholar
• Jung SP, Kim M, Choe JH, et al. Clinical implication of cancer adhesion in papillary thyroid carcinoma: clinicopathologic characteristics and prognosis analyzed with degree of extrathyroidal extension. World J Surg. 2013 Jul;37(7):1606–1613.
   PubMed Web of Science ®Google Scholar
• Ito Y, Tomoda C, Uruno T, et al. Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival. World J Surg. 2006 May;30(5):780–786.
   PubMed Web of Science ®Google Scholar
• Arora N, Turbendian HK, Scognamiglio T, et al. Extrathyroidal extension is not all equal: implications of macroscopic versus microscopic extent in papillary thyroid carcinoma. Surgery. 2008 Dec;144(6):942-7;discussion 947-8.
   PubMed Web of Science ®Google Scholar
• Jin BJ, Kim MK, Ji YB, et al. Characteristics and significance of minimal and maximal extrathyroidal extension in papillary thyroid carcinoma. Oral Oncol. 2015 Aug;51(8):759–763.
   PubMed Web of Science ®Google Scholar
• Moon HJ, Kim EK, Chung WY, et al. Minimal extrathyroidal extension in patients with papillary thyroid microcarcinoma: is it a real prognostic factor? Ann Surg Oncol. 2011 Jul;18(7):1916–1923.
   PubMed Web of Science ®Google Scholar
• Ahn D, Sohn JH, Jeon JH, et al. Clinical impact of microscopic extrathyroidal extension in patients with papillary thyroid microcarcinoma treated with hemithyroidectomy. J Endocrinol Invest. 2014 Feb;37(2):167–173.
   PubMed Web of Science ®Google Scholar
• Leboulleux S, Rubino C, Baudin E, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab. 2005 Oct;90(10):5723–5729.
   PubMed Web of Science ®Google Scholar
• Yamashita H, Noguchi S, Murakami N, et al. Extracapsular invasion of lymph node metastases is an indicator of distant metastases and poor prognosis in patients with thyroid papillary carcinoma. Cancer. 1997;80:2268–2272.
   PubMed Web of Science ®Google Scholar
• Ito Y, Tomoda C, Uruno T, et al. Minimal extrathyroid extension does not affect the relapse-free survival of patients with papillary thyroid carcinoma measuring 4 cm or less over the age of 45 years. Surg Today. 2006;36(1):12–18.
   PubMed Web of Science ®Google Scholar
• Lango M, Flieder D, Arrangoiz R, et al. Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic disease progression. Thyroid. 2013;23:1099–1105.
   PubMed Web of Science ®Google Scholar
• Clain JB, Scherl S, Dos RL, et al. Extrathyroidal extension predicts extranodal extension in patients with positive lymph nodes: an important association that may affect clinical management. Thyroid. 2014;24:951–957.
   PubMed Web of Science ®Google Scholar
• Nikiforov YEB, Paul W, Thompson LD. 2012 Diagnostic Pathology and Molecular Genetics of the Thyroid: A Comprehensive Guide for Practicing Thyroid Pathology. Baltimore, MD, USA: Lippincott Williams & Wilkins (LWW).
   Google Scholar
• Hawk WA, Hazard JB. The many appearances of papillary carcinoma of the thyroid. Cleve Clin Q. 1976;43:207–215.
   PubMedGoogle Scholar
• Leung AK, Chow SM, Law SC. Clinical features and outcome of the tall cell variant of papillary thyroid carcinoma. Laryngoscope. 2008;118:32–38.
   PubMed Web of Science ®Google Scholar
• Moreno EA, Rodriguez Gonzalez JM, Sola PJ, et al. Prognostic value of the tall cell variety of papillary cancer of the thyroid. Eur J Surg Oncol. 1993;19:517–521.
   PubMedGoogle Scholar
• Johnson TL, Lloyd RV, Thompson NW, et al. Prognostic implications of the tall cell variant of papillary thyroid carcinoma. Am J Surg Pathol. 1988;12:22–27.
   PubMed Web of Science ®Google Scholar
• Michels JJ, Jacques M, Henry-Amar M, et al. Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma. Hum Pathol. 2007;38:212–219.
   PubMed Web of Science ®Google Scholar
• Ghossein RA, Leboeuf R, Patel KN, et al. Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications. Thyroid. 2007;17:655–661.
   PubMed Web of Science ®Google Scholar
• Morris LG, Shaha AR, Tuttle RM, et al. Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival. Thyroid. 2010;20:153–158.
   PubMed Web of Science ®Google Scholar
• Ostrowski ML1, Merino MJ. Tall cell variant of papillary thyroid carcinoma: a reassessment and immunohistochemical study with comparison to the usual type of papillary carcinoma of the thyroid. Am J Surg Pathol. 1996;20(8):964–974.
   PubMed Web of Science ®Google Scholar
• DeLellis R, Lloyd R, Heitz P, et al. World Health Organization classification of tumours. In pathology and genetics of tumours of endocrine organs. Lyon, France: IARC Press; 2004.
   Google Scholar
• Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12:245–262.
   PubMed Web of Science ®Google Scholar
• Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399–5404.
   PubMed Web of Science ®Google Scholar
• Chen JH, Faquin WC, Lloyd RV, et al. Clinicopathological and molecular characterization of nine cases of columnar cell variant of papillary thyroid carcinoma. Mod Pathol. 2011;24:739–749.
   PubMed Web of Science ®Google Scholar
• Evans HL. Columnar-cell carcinoma of the thyroid. A report of two cases of an aggressive variant of thyroid carcinoma. Am J Clin Pathol. 1986;85:77–80.
   PubMed Web of Science ®Google Scholar
• Evans HL. Encapsulated columnar-cell neoplasms of the thyroid. A report of four cases suggesting a favorable prognosis. Am J Surg Pathol. 1996;20:1205–1211.
   PubMed Web of Science ®Google Scholar
• Wenig BM, Thompson LD, Adair CF, et al. Thyroid papillary carcinoma of columnar cell type: a clinicopathologic study of 16 cases. Cancer. 1998;82:740–753.
   PubMed Web of Science ®Google Scholar
• Asioli S, Erickson LA, Sebo TJ, et al. Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases. Am J Surg Pathol. 2010;34:44–52.
   PubMed Web of Science ®Google Scholar
• Motosugi U, Murata S, Nagata K, et al. Thyroid papillary carcinoma with micropapillary and hobnail growth pattern: a histological variant with intermediate malignancy? Thyroid. 2009;19:535–537.
   PubMed Web of Science ®Google Scholar
• Lubitz CC, Economopoulos KP, Pawlak AC, et al. Hobnail variant of papillary thyroid carcinoma: an institutional case series and molecular profile. Thyroid. 2014;24:958–965.
   PubMed Web of Science ®Google Scholar
• Mizukami Y, Noguchi M, Michigishi T, et al. Papillary thyroid carcinoma in Kanazawa, Japan: prognostic significance of histological subtypes. Histopathology. 1992;20:243–250.
   PubMed Web of Science ®Google Scholar
• Nikiforov YE, Erickson LA, Nikiforova MN, et al. Solid variant of papillary thyroid carcinoma: incidence, clinical-pathologic characteristics, molecular analysis, and biologic behavior. Am J Surg Pathol. 2001;25:1478–1484.
   PubMed Web of Science ®Google Scholar
• Akslen LA, LiVolsi VA. Poorly differentiated thyroid carcinoma–it is important. Am J Surg Pathol. 2000;24(2):310–313.
   PubMed Web of Science ®Google Scholar
• Sobrinho-Simões M, Sambade C, Fonseca E, et al. Poorly differentiated carcinomas of the thyroid gland: a review of the clinicopathologic features of a series of 28 cases of a heterogeneous, clinically aggressive group of thyroid tumors. Int J Surg Pathol. 2002;10(2):123–131.
   PubMed Web of Science ®Google Scholar
• Hiltzik D, Carlson DL, Tuttle RM, et al. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer. 2006;15;106(6):1286–1295.
   Web of Science ®Google Scholar
• Carcangiu ML, Zampi G, Rosai J. Poorly differentiated (“insular”) thyroid carcinoma. A reinterpretation of Langhans’ “wuchernde Struma”. Am J Surg Pathol. 1984;8(9):655–668.
   PubMed Web of Science ®Google Scholar
• Sakamoto A, Kasai N, Sugano H. Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer. 1983;15;52(10):1849–1855.
   Web of Science ®Google Scholar
• Volante M, Collini P, Nikiforov YE, et al. Poorly differentiated thyroid carcinomas: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol. 2007;31:1256–1264.
   PubMed Web of Science ®Google Scholar
• Asioli S, Erickson LA, Righi A, et al. Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. Mod Pathol. 2010;23:1269–1278.
   PubMedGoogle Scholar
• Ito Y, Hirokawa M, Fukushima M, et al. Prevalence and prognostic significance of poor differentiation and tall cell variant in papillary carcinoma in Japan. World J Surg. 2008;32(7):1535-43;discussion 1544-5.
   Web of Science ®Google Scholar
• Lam AK, Lo CY. Diffuse sclerosing variant of papillary carcinoma of the thyroid: a 35-year comparative study at a single institution. Ann Surg Oncol. 2006;13:176–181.
   PubMed Web of Science ®Google Scholar
• Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016;2(8):1023–1029.
   PubMed Web of Science ®Google Scholar
• Elisei R, Viola D, Torregrossa L, et al. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab. 2012;97(12):4390–4398.
   PubMed Web of Science ®Google Scholar
• Kim TH, Park YJ, Lim JA, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer. 2012;1;118(7):1764–1773.
   PubMed Web of Science ®Google Scholar
• Li C, Lee KC, Schneider EB, et al. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol. 2012;97(12):4559–4970.
   PubMed Web of Science ®Google Scholar
• Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. Jama. 2013;309(14):1493–1501.
   PubMed Web of Science ®Google Scholar
• Koperek O, Kornauth C, Capper D, et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol. 2012;36(6):844–850.
   PubMed Web of Science ®Google Scholar
• Ito Y1, Yoshida H, Maruo R, et al., BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J. 2009;561:89–97. Epub 2008 Oct 8.
   PubMed Web of Science ®Google Scholar
• Kim TY, Kim WB, Song JY, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf). 2005;63(5):588–593.
   PubMed Web of Science ®Google Scholar
• Blasco MA. Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet. 2005;6(8):611–622.
   PubMed Web of Science ®Google Scholar
• Xing M, Liu R, Liu X, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol. 2014;32(25):2718–2726.
   PubMed Web of Science ®Google Scholar
• Shi X, Liu R, Qu S, et al. Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer. J Clin Endocrinol Metab. 2015;100(4):E632–7.
   PubMed Web of Science ®Google Scholar
• Song YS, Lim JA, Choi H, et al. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients. Cancer. 2016;122(9):1370–1379.
   PubMed Web of Science ®Google Scholar
• Bae JS, Kim Y, Jeon S, et al. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation. Diagn Pathol. 2016;11:21.
   PubMed Web of Science ®Google Scholar
• Myung JK, Kwak BK, Lim JA, et al. TERT promoter mutations and tumor persistence/recurrence in papillary thyroid cancer. Cancer Res Treat. 2016;48(3):942–947.
   PubMedGoogle Scholar
• Gandolfi G, Ragazzi M, Frasoldati A, et al. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma. Eur J Endocrinol. 2015;172(4):403–413.
   PubMed Web of Science ®Google Scholar
• Lee SE, Hwang TS, Choi YL, et al. Prognostic significance of TERT promoter mutations in papillary thyroid carcinomas in a BRAF(V600E) mutation-prevalent population. Thyroid. 2016;26(7):901–910.
   PubMed Web of Science ®Google Scholar
• Liu R, Bishop J, Zhu G, et al. Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality. JAMA Oncol. 2016. [ Epub ahead of print].
   Google Scholar
• Jin L, Chen E, Dong S, et al. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients. Oncotarget. 2016;7(14):18346–18355.
   PubMed Web of Science ®Google Scholar